The microtubule cytoskeleton: An old validated target for novel therapeutic drugs
- PMID: 36188585
- PMCID: PMC9521402
- DOI: 10.3389/fphar.2022.969183
The microtubule cytoskeleton: An old validated target for novel therapeutic drugs
Abstract
Compounds targeting microtubules are widely used in cancer therapy with a proven efficacy. However, because they also target non-cancerous cells, their administration leads to numerous adverse effects. With the advancement of knowledge on the structure of tubulin, the regulation of microtubule dynamics and their deregulation in pathological processes, new therapeutic strategies are emerging, both for the treatment of cancer and for other diseases, such as neuronal or even heart diseases and parasite infections. In addition, a better understanding of the mechanism of action of well-known drugs such as colchicine or certain kinase inhibitors contributes to the development of these new therapeutic approaches. Nowadays, chemists and biologists are working jointly to select drugs which target the microtubule cytoskeleton and have improved properties. On the basis of a few examples this review attempts to depict the panorama of these recent advances.
Keywords: drug development; microtubule regulations; microtubules; targeted therapies; tubulin; tubulin post-translational modifications; tubulin-binding drugs.
Copyright © 2022 Lafanechère.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Publication types
LinkOut - more resources
Full Text Sources
